This disease of colder months in temperate areas is practically non-existent in the U.S. due to an aggressive vaccination program for the past several decades. We currently see less than 5 cases of respiratory diphtheria annually. This dangerous respiratory disease is caused by a potent toxin produced by certain strains...
Latest News
New York, NY – A new vaccine shows encouraging early results as a potential off-the-shelf treatment for certain patients with pancreatic or colorectal cancer, according to a study co-led by researchers at Memorial Sloan Kettering Cancer Center (MSK). The vaccine targets tumors with mutations (or changes) in the KRAS gene, a driving...
TOKYO & MUNICH & BASKING RIDGE, N.J. – New data from Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) for valemetostat, a potential first-in-class specific and potent dual inhibitor of EZH1 and EZH2, showed promising and durable tumor response in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) and adult T-cell leukemia/lymphoma...
A Valley boy diagnosed with a rare and fatal childhood disease is now being allowed access to an experimental drug. Denise and Rickey Miller’s 21-month-old son Woodrow has Niemann-Pick Disease Type C. It’s a form of childhood Alzheimer’s that eventually takes away the child’s ability to walk, talk, swallow, and breathe. For...
Saint-Herblain, France – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive final antibody persistence and safety data for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ®, in 304 children, twelve months after vaccination....
GRAND RAPIDS, Mich. (April 16, 2024) — A new study from Van Andel Institute scientists offers a first look into the complex molecular changes that occur in brain cells with Lewy bodies, which are key pathological hallmarks of Parkinson’s disease and some dementias. The findings, published in the journal Nature Communications, reveal...
WASHINGTON, DC — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for imsidolimab, a novel IgG4 IL-36 receptor antagonist, to treat generalized pustular psoriasis (GPP). Imsidolimab inhibits IL-36 receptor signaling, addressing the deficiency in the endogenous IL-36RA...
WASHINGTON, DC — Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its PONVORY® (ponesimod) patent application, number 17/962,968, covering methods for reducing clinical management events before or during the treatment of multiple sclerosis and methods for reinitiating...
WASHINGTON, DC — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the first dose in the first-in-human clinical trial to evaluate the safety and tolerability of VCA-894A, an antisense oligonucleotide (ASO) therapeutic, for a patient with a rare variant in the IGHMBP2 gene causing Charcot-Marie-Tooth disease Type 2S (CMT2S). VCA-894A is being developed for a patient who was...
WASHINGTON, DC — Vanda Pharmaceuticals, Inc. today announced the publication of an article titled “The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial” in the Clinical Gastroenterology and Hepatology Journal which follows a previously published study of tradipitant in the treatment...